Charles River Laboratories International, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 3.54B | 3.98B | 4.13B | 4.05B | 4.02B | -0.9% | |
| Cost of Revenue | (2.21B) | (2.51B) | (2.63B) | (2.72B) | (2.79B) | 2.6% | |
Gross Profit | 1.33B | 1.46B | 1.50B | 1.33B | 1.23B | -8.0% | |
| Operating Expenses | |||||||
| Research & Development | — | — | — | — | — | — | |
| Selling, General & Administrative | (619.92M) | (665.10M) | (747.86M) | (751.00M) | (743.07M) | -1.1% | |
| Depreciation & Amortization | (265.54M) | (303.87M) | (314.12M) | (361.74M) | (403.31M) | 11.5% | |
Operating Income (EBIT) | 589.86M | 650.98M | 617.26M | 227.35M | 507.84M | 123.4% | |
| Non-Operating Items | |||||||
| Interest Income | 652.00K | 780.00K | 5.20M | 8.57M | 4.94M | -42.4% | |
| Interest Expense | (73.91M) | (59.29M) | (136.71M) | (126.29M) | (107.03M) | -15.3% | |
| Other Income/Expenses (Net) | -109.15M | -27.99M | -35.98M | -134.23M | -607.34M | 352.5% | |
Income Before Tax | 480.71M | 622.99M | 581.28M | 93.11M | -99.50M | -206.9% | |
| Income Tax Expense | (81.87M) | (130.38M) | (100.91M) | (67.82M) | (42.66M) | -37.1% | |
Net Income | 390.98M | 486.23M | 474.62M | 10.30M | -144.34M | -1501.7% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $8 | $10 | $9 | $0 | $-3 | -1555.0% | |
| Weighted Avg Shares Outstanding | 50.29M | 50.81M | 51.23M | 51.38M | 49.56M | -3.5% | |
| Weighted Avg Shares Outstanding (Diluted) | 51.42M | 51.30M | 51.45M | 51.63M | 49.56M | -4.0% | |
EBITDA | 820.16M | 986.15M | 1.03B | 581.14M | 410.84M | -29.3% |
Explore CRL
CRL in the Healthcare
Large Cap